Long Non-Coding RNAs Roles in Tumorigenesis of Esophageal Carcinoma

Abstract

Background:Esophageal carcinoma (ESCA) is one of the most common types of cancer. ESCA is accounted for the sixth leading cause of cancer-related deaths globally. The majority of the patients are diagnosed at late stages of ESCA, with distance metastasis and/or chemoresistance, which lead to a poor prognosis. Previous studies demonstrated lncRNA presentation and roles in ESCA cells and patients tissue. It has been proposed that lncRNAs can be considered as a new prognostic and diagnostic biomarker in ESCA. This study comprehensively explored the interaction of lncRNAs with miRNAs and mRNAs of TCGA database and proposed novel promising biomarker with favorable diagnostic and prognostic values. Methods: The public data of RNA-seq, miR-seq and related clinical data were downloaded from TCGA database. Differential expression analysis was conducted by “limma” in R. GO and KEGG signaling pathway were used for enrichments. STRING database was used for PPI analysis. CE-network was constructed by STAR database in R. Kaplan-Meier survival analysis (log-rank test) and ROC curve analysis to indicate the biomarkers' diagnostic and prognostic values.Results: Differentially expressed data illustrated that 1332 mRNA including 610 upregulated and 722 down-regulated were differentially expressed in ESCA.The GO and KEGG pathway analysis showed that the differentially expressed mRNAs were enriched in critical biological processes. The PPI showed that IGFBP5, ACAN, ADAMTS12, MMP13, and CDH2 were the important PPI hubs. The ceRNA network data demonstrated critical lncRNAs including TMEM16B-AS1, AC093010.3, SNHG3, and PVT1 which have an essential role in ESCA development.The data revealed that the lncRNA WDFY3-AS2, AC108449.2,DLEU2, AC007128.1, and AP003356.1 are potential diagnostic prognostic biomarker in the ESCA patients. Conclusion: Altogether, in our study, we demonstrated lncRNA, miRNA, and mRNA interaction and mentioned regulatory networks, which can be considered as a therapeutic option in ESCA. In addition, we proposed potential diagnostic and prognostic biomarkers for the patients.